The regulation of PD-1/PD-L1 pathway and autoimmune diseases

被引:0
|
作者
Okazaki, T [1 ]
Iwai, Y [1 ]
Nishimura, H [1 ]
Honjo, T [1 ]
机构
[1] Kyoto Univ, Dept Med Chem, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan
关键词
autoimmune disease; dilated cardiomyopathy; autoantibody;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PD-1 is an immuno-inhibitory receptor which belongs to the immunoglobulin superfamily and expressed on activated T, B and myeloid cells. Engagement of the PD-1 receptor with its membrane bound ligand (PD-LI) of the B7 family inhibits the proliferation of anti-CD3 stimulated T cells as well as anti-IgM stimulated B cells (Freeman et al. 2000 and our unpublished observation). Disruption of PD-1 gene in C57BL/6 mice caused typical lupus-like glomerulonephritis and destructive arthritis as they age (Nishimura et al. 1999) while in BALB/c mice caused autoantibody mediated dilated cardiomyopathy with severely impaired contraction and sudden death by congestive heart failure. Affected hearts showed diffuse deposition of IgG on the surface of cardiomyocytes. All of the affected PD-1(-/-) mice exhibited high-titered circulating IgG autoantibodies reactive to a 33-kDa protein expressed specifically on the surface of cardiomyocytes (Nishimura et al. 2001). These results indicate that PD-1 may be an important factor contributing to the prevention of autoimmune diseases.
引用
收藏
页码:211 / 214
页数:4
相关论文
共 50 条
  • [41] PD-1 and PD-L1 prognostic in UTUC
    Louise Stone
    Nature Reviews Urology, 2017, 14 : 518 - 518
  • [42] PD-1 and PD-L1 antibodies for melanoma
    Tsai, Katy K.
    Zarzoso, Ines
    Daud, Adil I.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116
  • [43] PD-1/PD-L1 in cardiovascular disease
    Sun, YunFeng
    Li, Liang
    Wu, YaWei
    Yang, KePing
    CLINICA CHIMICA ACTA, 2020, 505 : 26 - 30
  • [44] Expression of PD-1, PD-L1, and PD-L2 in the liver in autoirnmune liver diseases
    Mataki, Norikazu
    Kikuchi, Kentaro
    Kawai, Toshihiro
    Higashiyama, Masaaki
    Okada, Yoshikiyo
    Kurihara, Chle
    Hokari, Ryota
    Kawaguchi, Atsushi
    Nagao, Shigeaki
    Kondo, Toshiro
    Itoh, Kazuro
    Miyakawa, Hiroshi
    Miura, Soichiro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (02): : 302 - 312
  • [45] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Annika De Sousa Linhares
    Claire Battin
    Sabrina Jutz
    Judith Leitner
    Christine Hafner
    Joshua Tobias
    Ursula Wiedermann
    Michael Kundi
    Gerhard J. Zlabinger
    Katharina Grabmeier-Pfistershammer
    Peter Steinberger
    Scientific Reports, 9
  • [46] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Linhares, Annika De Sousa
    Battin, Claire
    Jutz, Sabrina
    Leitner, Judith
    Hafner, Christine
    Tobias, Joshua
    Wiedermann, Ursula
    Kundi, Michael
    Zlabinger, Gerhard J.
    Grabmeier-Pfistershammer, Katharina
    Steinberger, Peter
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [47] FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents.
    Weinstock, Chana
    Singh, Harpreet
    Maher, Virginia Ellen
    Kim, Geoffrey
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [49] The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease
    Weyand, Cornelia M.
    Berry, Gerald J.
    Goronzy, Jorg J.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2018, 103 (03) : 565 - 575
  • [50] Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
    Zhang, Min
    Liu, Kehai
    Wang, Mingfu
    RSC ADVANCES, 2019, 9 (58) : 33903 - 33911